The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.873
https://www.valueinhealthjournal.com/article/S1098-3015(14)02803-4/fulltext
Title :
The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02803-4&doi=10.1016/j.jval.2014.08.873
First page :
A393
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
388